Financial Performance - The company's operating revenue for Q1 2025 was ¥2,429,825,335.81, a decrease of 1.81% compared to ¥2,474,697,457.66 in the same period last year[5] - Net profit attributable to shareholders was ¥112,095,257.24, down 20.99% from ¥141,879,437.62 year-on-year[5] - Basic and diluted earnings per share were both ¥0.15, representing a decline of 28.57% from ¥0.21 in the same period last year[5] - Total comprehensive income for the current period was 104,998,682.16, down from 146,079,426.17 in the previous period, a decrease of about 28.2%[20] - Net profit for the current period was 115,643,803.12, down from 145,264,098.40 in the previous period, representing a decrease of approximately 20.4%[19] Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 77.87%, amounting to ¥8,425,190.10 compared to ¥38,063,364.43 in the previous year[5] - Cash flow from operating activities generated a net amount of 8,425,190.10, significantly lower than 38,063,364.43 in the previous period[21] - The decline in net cash flow from operating activities was attributed to an increase in the proportion of bank acceptance bill collections and a decrease in inventory changes compared to the previous year[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,269,855,861.11, an increase of 2.77% from ¥9,019,601,567.53 at the end of the previous year[5] - The total current assets increased to ¥3,999,396,150.59 from ¥3,726,840,162.91, reflecting a growth of about 7.3%[16] - Accounts receivable rose significantly to ¥1,200,307,190.06, up from ¥868,204,001.79, indicating an increase of approximately 38.2%[16] - The total liabilities increased to ¥3,879,907,761.23 from ¥3,802,101,150.19, marking a rise of about 2.0%[17] - The non-current liabilities decreased to ¥645,097,935.77 from ¥1,006,487,037.80, a reduction of approximately 35.9%[17] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 3.28% to ¥5,155,519,978.65 from ¥4,991,588,524.78[5] - The total equity attributable to shareholders increased to ¥5,155,519,978.65 from ¥4,991,588,524.78, indicating a growth of approximately 3.3%[17] Expenses - Research and development expenses for the current period were 109,788,595.18, compared to 141,905,763.44 in the previous period, showing a reduction of approximately 22.6%[19] - The company reported a decrease in sales expenses from 291,064,033.27 in the previous period to 99,952,491.15 in the current period, a reduction of about 65.6%[19] - The company's total operating costs decreased from 2,328,929,009.30 to 2,299,988,387.70, a reduction of approximately 1.2%[19] Other Income and Changes - The company reported non-operating income of ¥7,067,182.83, primarily from government subsidies and asset disposal gains[7] - The company approved changes to accounting policies that are not expected to have a significant impact on the financial statements[13] - The company experienced an investment loss of 760,243.82 in the current period, compared to a gain of 1,188,728.16 in the previous period[19]

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the supplementary application of Mecobalamin tablets, allowing the transfer of the marketing authorization holder [1] Company Summary - The transaction does not require approval from the company's board of directors or shareholders, as it does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1] - Mecobalamin tablets are indicated for peripheral neuropathy and are listed as a Class B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog [1] Industry Summary - In 2023, the sales revenue of Mecobalamin tablets in Chinese public medical institutions is approximately RMB 1.431 billion [1]

Financial Performance - The financial summary indicates that the company achieved a revenue of RMB 1.2 billion, representing a year-over-year growth of 15%[11] - The net profit for the reporting period was RMB 300 million, which is an increase of 20% compared to the previous year[12] - Operating income for 2024 reached RMB 8,466,309,803.08, an increase of 4.51% compared to RMB 8,100,844,707.33 in 2023[15] - Net profits attributable to shareholders of the listed company decreased by 5.33% to RMB 470,023,746.08 from RMB 496,512,201.25 in 2023[15] - Net cash flow from operating activities increased by 38.58% to RMB 367,610,448.95 compared to RMB 265,278,895.87 in 2023[15] - Total assets grew by 8.85% to RMB 9,019,601,567.53 from RMB 8,286,166,330.90 at the end of 2023[15] - Total liabilities increased by 8.31% to RMB 3,802,101,150.19 from RMB 3,510,413,044.14 at the end of 2023[15] - Basic earnings per share for 2024 was RMB 0.69, a decrease of 6.76% from RMB 0.74 in 2023[15] - The ratio of weighted average return on net assets decreased by 1.62 percentage points to 9.79% from 11.41% in 2023[15] - Net profits attributable to shareholders after deduction of non-recurring profit or loss was RMB 448,006,721.77, down 2.93% from RMB 461,535,415.37 in 2023[15] - Minority interest income increased by 73.96% to RMB 16,690,827.80 from RMB 9,594,823.76 in 2023[15] Revenue Guidance and Growth Projections - The company has set a revenue guidance of RMB 1.5 billion for the next fiscal year, projecting a growth rate of 25%[14] - User data shows that the active user base grew to 5 million, reflecting a 25% increase from the last fiscal year[13] - New product launches contributed to 30% of total revenue, highlighting the success of recent innovations[11] - Market expansion efforts have led to a 10% increase in market share in the domestic market[13] Research and Development - The company is investing RMB 200 million in R&D for new technologies aimed at enhancing product efficacy[12] - The company is exploring potential acquisitions to enhance its product portfolio and market presence[14] - Strategic initiatives include partnerships with local distributors to improve supply chain efficiency[11] Shareholder Information - The top shareholder, Hualu Holdings Group Co. Ltd., holds 30.02% of the total share capital, amounting to 204,864,092 shares[31] - The number of registered shareholders increased from 76,496 to 78,450 between December 31, 2024, and February 28, 2025[32] - The company issued 7,724,800 new A-shares due to the exercise of stock options, which were registered and listed for circulation on January 15, 2024[27] - The total number of unconditional tradable shares as of December 31, 2024, was 643,774,361, slightly up from 636,006,160 the previous year, indicating an increase of approximately 1.21%[26] - The shareholding of domestic legal person shares remained stable at 37,091,988, accounting for 5.44% of the total share capital[31] - The number of shares held by the second-largest shareholder, HKSCC (Nominees) Limited, is 193,314,147, representing 28.33% of the total share capital[31] - There were no pledges or freezes on the shares held by the top ten shareholders[37] Corporate Governance - The Company has established effective internal controls in all material aspects according to the Basic Standards for Corporate Internal Control, achieving its internal control objectives without any significant deficiencies[166] - The Company has complied with all code provisions set out in the Corporate Governance Code for the year ended December 31, 2024[169] - The Board of Directors regularly evaluates Senior Officers based on their performance and adherence to resolutions[155] - The Company has established a clear incentive and penalty scheme for Senior Officers to ensure accountability[156] - The Company strictly fulfilled its information disclosure obligations, ensuring the truthfulness and completeness of disclosed information[153] Management and Leadership - The Company has a diverse management team with expertise in engineering, economics, and pharmaceutical fields[88] - The management team has held various positions within the Company, indicating a strong internal promotion culture[84] - The Company emphasizes the importance of experienced leadership with long tenures in key positions[82] - The current term of the Directors, Supervisors, and Senior Officers of the Company is until December 22, 2026[86] Employee Information and Training - As of December 31, 2024, the Group employed 7,296 staff with total wages amounting to RMB 743,487,000[104] - The staff distribution by area of work includes 4,060 production personnel, 946 sales personnel, and 561 research and development personnel[105] - The education level of employees shows that 2,037 hold university degrees or above, while 2,489 have tertiary education[107] - In 2024, the Company completed 79 corporate-level education training programs, training over 4,600 employees[112] Audit and Compliance - Grant Thornton Zhitong Certified Public Accountants LLP issued a standard unqualified audit report for the financial statements as of December 31, 2024, reflecting the company's financial condition accurately[134] - The Audit Committee recommended the reappointment of Grant Thornton Zhitong as the financial auditor for the year 2025[140] - The Company engaged Zhitong to conduct an independent audit on the effectiveness of its internal control[158] Diversity and Inclusion - The Company achieved its goal of having at least one female Director by 31 December 2024, with the current Board comprising eight male members and one female member[200] - Female representation at the workforce level has reached approximately 42.58%, achieving gender diversity across the workforce[200] - The Board adopted a diversity policy to ensure a balance of skills, experience, and perspectives appropriate to the Company's business needs[199]

Financial Performance - The company's operating revenue for Q1 2025 was RMB 2,429,825,335.81, a decrease of 1.81% compared to RMB 2,474,697,457.66 in Q1 2024[6] - Net profit attributable to shareholders for Q1 2025 was RMB 112,095,257.24, down 20.99% from RMB 141,879,437.62 in the same period last year[6] - The net profit after deducting non-recurring gains and losses was RMB 105,028,074.41, reflecting a decline of 23.74% year-on-year[6] - The total comprehensive income for Q1 2025 was RMB 104,998,682.16, down from RMB 146,079,426.17 in the same period last year[10] Cash Flow - The net cash flow from operating activities decreased significantly by 77.87%, amounting to RMB 8,425,190.10 compared to RMB 38,063,364.43 in Q1 2024[6] Earnings and Returns - Basic and diluted earnings per share for Q1 2025 were both RMB 0.15, a decrease of 28.57% from RMB 0.21 in Q1 2024[8] - The weighted average return on equity was 2.21%, down 0.83 percentage points from 3.04% in the previous year[8] Assets and Equity - Total assets as of March 31, 2025, were RMB 9,269,855,861.11, an increase of 2.77% from RMB 9,019,601,567.53 at the end of 2024[8] - Net assets attributable to shareholders increased by 3.28% to RMB 5,155,519,978.65 from RMB 4,991,588,524.78 at the end of 2024[8] Research and Development - Research and development expenses for Q1 2025 were RMB 109,788,595.18, compared to RMB 141,905,763.44 in Q1 2024[9] Accounting Policies - The company has implemented changes to accounting policies as per the Ministry of Finance's issuance of "Interpretation No. 18" effective from December 31, 2024, which addresses accounting treatment for quality assurance not related to individual performance obligations[11] - The changes in accounting policies were approved by the company's board on March 28, 2025, and are not expected to have a significant impact on the group's financial statements[11]

Group 1: Company Growth and Innovation Strategies - The company is focusing on establishing innovation platforms with renowned research institutions to enhance high-value new drug development and accelerate results transformation [2][3] - There are over 100 drugs in the research pipeline, including multiple first-class innovative drugs like OAB-14 for Alzheimer's treatment [3][4] - The company aims to deepen internationalization and strengthen its position in the high-value raw material drug market [2][3] Group 2: Financial Performance and Market Position - In 2024, the company achieved a revenue of 8.466 billion yuan, representing a year-on-year growth of 4.51% [6][9] - The company emphasizes cash dividends, with the cash dividend ratio significantly exceeding the stipulated proportion in its articles of association [2][3] - The company's price-to-earnings ratio is lower than most pharmaceutical companies, raising concerns about potential stock buybacks [2][6] Group 3: Cost Control and Efficiency Measures - The company implements comprehensive budget management to control expenses and enhance operational efficiency [3][4] - Measures include optimizing procurement processes and production operations to reduce costs while maintaining quality [3][4] Group 4: Market Challenges and Stock Performance - Despite the approval of multiple new products, the stock price has been declining, influenced by market competition, industry policies, and investor sentiment [5][9] - The company acknowledges the impact of macroeconomic uncertainties and competitive pressures on its market value [9][10] Group 5: Investor Relations and Communication - The company is committed to enhancing communication with investors through regular reports and performance briefings [6][9] - The recent investor relations activities aim to rebuild investor confidence and clarify the company's strategic direction [6][9] Group 6: Industry Outlook - The pharmaceutical industry is expected to grow due to increasing health awareness and an aging population, with innovation driving new drug development [11]

Financial Performance - The total operating revenue for the fiscal year 2024 reached RMB 8,466,309,803.08, representing a 4.51% increase compared to RMB 8,100,844,707.33 in 2023[10] - The net profit attributable to shareholders of the listed company decreased by 5.33% to RMB 470,023,746.08 from RMB 496,512,201.25 in the previous year[10] - The basic earnings per share for 2024 was RMB 0.69, a decrease of 6.76% from RMB 0.74 in 2023[10] - The company proposes a final dividend of RMB 0.25 per share for the year 2024, based on a total issued share count of 689,776,535 shares[19] - The company reported a total comprehensive income of RMB 542,947,084.11, compared to RMB 507,843,039.72 in the previous year, representing an increase of 6.9%[77] - The net profit for the year was RMB 486,714,573.88, a decrease of 3.1% compared to RMB 506,107,025.01 in 2023[77] - The total income tax expense for 2024 reached RMB 46,938,849.44, compared to RMB 26,578,700.01 in 2023, which is an increase of approximately 76.7%[107] - The company reported a total of RMB 187,662,099.63 in dividends for the year 2024, up from RMB 134,936,567.00 in 2023, indicating a growth of about 39.0%[112] Assets and Liabilities - The total assets as of the end of 2024 increased by 8.85% to RMB 9,019,601,567.53 compared to RMB 8,286,166,330.90 at the end of 2023[10] - The total liabilities increased by 8.31% to RMB 3,802,101,150.19 from RMB 3,510,413,044.14 in the previous year[9] - The company's asset-liability ratio stood at 42.15%[41] - The total debt of the company was RMB 1,663,214,000, with cash and cash equivalents amounting to RMB 1,245,023,000[38] - Current assets totaled RMB 3,726,840,162.91 as of December 31, 2024, compared to RMB 3,314,333,616.01 in the previous year, indicating an increase of about 12.48%[72] - The company reported a total inventory of RMB 1,272,856,947.10 as of December 31, 2024, slightly down from RMB 1,312,983,676.75 in 2023, indicating a decrease of about 3.06%[72] Cash Flow - The net cash flow from operating activities improved by 38.58% to RMB 367,610,448.95 from RMB 265,278,895.87 in 2023[10] - Cash and cash equivalents increased by 35.57% to ¥1,245,022,873.47 from ¥918,334,462.29, primarily due to increased bank deposits to meet investment needs[26] - Operating cash inflow increased by 16.06% to ¥8,190,329,183.85 from ¥7,057,191,280.19, driven by enhanced operational efficiency and faster inventory turnover[33] - The net increase in cash and cash equivalents was ¥355,190,755.19, a significant improvement of 255.05% compared to a decrease of ¥229,080,092.64 in the previous year[33] Shareholder Information - The number of registered shareholders as of December 31, 2024, was 76,496, including 39 H-share and 76,457 A-share shareholders[13] - The company issued an additional 7,368,900 A-shares due to the stock option incentive plan during the reporting period[8] - The total number of shares held by major shareholders includes 204,864,092 RMB ordinary shares and 193,314,147 overseas listed foreign shares[16] - The total number of shares held by directors and senior management as of December 31, 2024, is 2,055,050 shares, an increase from 1,215,250 shares in 2023[20] Market and Product Development - The company plans to continue expanding its market presence and invest in new product development to drive future growth[10] - The company achieved sales revenue from new pharmaceutical products, with 22 new formulation product approvals and 5 new raw material drug approvals during the year[45] - The company plans to launch over 50 new products in the next two years, providing strong support for innovation breakthroughs and goal completion by 2025[50] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[85] Operational Efficiency - The company reported a 25.05% decrease in selling expenses, totaling ¥584,739,997.94 compared to ¥780,171,394.31, reflecting cost control measures[30] - The company experienced a 76.60% increase in income tax expenses, amounting to ¥46,938,849.44, attributed to higher profitability in a higher tax rate environment[30] - The company’s liquidity ratios include a current ratio of 133.31% and a quick ratio of 87.78% as of December 31, 2024[37] Research and Development - Research and development expenses were RMB 413,182,811.71, slightly down from RMB 419,239,700.90 in 2023[76] - The goal is to obtain over 15 drug approvals in the year, enhancing the R&D and transformation capabilities of active pharmaceutical ingredients[54] - The company is advancing the development of innovative drugs like OAB-14 and optimizing production processes to enhance competitiveness[55] Strategic Initiatives - The company completed the acquisition of its wholly-owned subsidiary, Ronghua (Zibo) Property Service Co., Ltd.[38] - The company introduced a green channel mechanism for R&D and production transformation, enhancing development vitality and achieving the introduction of 1 Chinese Academy of Engineering academician and 2 national key talent project members[48] - The company’s strategic cooperation with leading enterprises in the commercial sector has deepened, enhancing its market control[46]

Financial Performance - The company's operating revenue for the six months ended June 30, 2024, was RMB 4,732,481,467.24, representing a 1.29% increase compared to RMB 4,672,269,049.13 for the same period in 2023[8]. - Total profit for the same period was RMB 303,363,837.69, a decrease of 8.61% from RMB 331,945,812.26 in the previous year[8]. - Net profit attributable to shareholders of the listed company was RMB 265,404,417.68, down 1.63% from RMB 269,807,157.85 in the prior year[8]. - The net cash flow from operating activities increased significantly by 284.49%, reaching RMB 77,401,054.87 compared to RMB 20,131,070.66 in the previous year[8]. - Operating revenue for the first half of 2024 reached RMB 4,732,481,467.24, a 1.29% increase compared to RMB 4,672,269,049.13 in the same period of 2023[55]. - Operating costs increased by 8.13% to RMB 3,547,931,805.24 from RMB 3,281,046,254.21 year-on-year[55]. - The gross profit margin decreased by 4.75 percentage points to 25.03% from the previous year[58]. - The company reported a net profit of RMB 303,363,837.69 for the first half of 2024, down from RMB 532,685,725.02 in the same period of 2023[59]. - The total comprehensive income for the period was RMB 300,093,254.25, compared to RMB 289,553,439.14, reflecting an increase of about 3.5%[100]. - The company reported a total comprehensive income of RMB 238,097,470.11 for the first half of 2024, down from RMB 358,104,139.33 in the same period last year[101]. Shareholder Information - The company plans to distribute an interim dividend of RMB 0.25 per 10 shares, based on a total share capital of 682,407,635 shares[5]. - The total number of shareholders is 86,475, including 39 H-share shareholders and 86,436 A-share shareholders[13]. - The total number of shares as of June 30, 2024, is 682,407,635, with 94.34% being unrestricted shares[12]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.02% of the shares, totaling 204,864,092 shares[14]. - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 28.33% of the shares, totaling 193,314,147 shares[14]. - The number of restricted circulating shares is 38,633,274, accounting for 5.66% of the total share capital[12]. - The number of unrestricted circulating shares is 643,774,361, accounting for 94.34% of the total share capital[12]. - The shareholding structure shows no changes in the controlling shareholder or actual controller during the reporting period[18]. - The total salary paid to directors, supervisors, and senior management during the reporting period is RMB 2,011,825, with an additional RMB 6,390,878 for exercised stock options[22]. - The total number of A-shares held by directors, supervisors, and senior management is 2,055,050, representing approximately 0.4216% of the total issued A-shares[19]. Employee Information - The total number of employees in the group as of June 30, 2024, is 7,064, with a total salary expenditure of RMB 410,054,000 for the half-year period[23]. - The employee distribution by function includes 3,873 production personnel, 643 engineering technicians, and 940 sales personnel[24]. - The educational background of employees shows that 1,893 have a university degree or higher, while 2,328 have a college degree[25]. - The company has conducted 46 training sessions in the first half of 2024, with 2,321 participants, focusing on various professional skills and safety knowledge[25]. - The company has no retired employees or bonuses distributed during the reporting period[23]. Research and Development - The company launched 7 new formulation products in the first half of 2024, with 12 additional products in the pipeline[38]. - The company obtained 14 new product approvals and 6 consistency evaluation approvals in the first half of 2024[40]. - The company completed Phase I clinical trials for the innovative drug OAB-14 targeting Alzheimer's disease[40]. - Research and development expenses rose by 2.72% to RMB 231,912,142.60 compared to RMB 225,778,632.69 in the previous year[55]. - The company has established a roadmap for 91 innovation breakthrough projects for 2024[41]. - The company aims to accelerate the development of new products and market expansion, targeting the launch of at least 20 new products by the end of the year[47]. Financial Position - Total assets as of June 30, 2024, amounted to RMB 8,733,859,124.56, reflecting a 5.40% increase from RMB 8,286,166,330.90 at the end of 2023[8]. - Total liabilities increased by 7.09% to RMB 3,759,211,551.82 from RMB 3,510,413,044.14 at the end of 2023[8]. - The asset-liability ratio of the group stands at 43.04% as of June 30, 2024, reflecting a stable capital structure[61]. - The total capital debt ratio is 29.42% and the net capital debt ratio is 8.46%, indicating a manageable level of debt[61]. - The total current assets reached RMB 3,638,665,068.80, an increase from RMB 3,314,333,616.01 as of December 31, 2023, representing a growth of approximately 9.8%[94]. - The accounts receivable increased to RMB 1,022,661,555.32 from RMB 699,877,948.91, reflecting a growth of about 46.1%[94]. - The total equity attributable to shareholders increased to RMB 4,754,065,944.57 from RMB 4,553,103,869.56, showing an increase of about 4.41%[95]. - The total liabilities of the company at the end of June 2024 were RMB 2,122,924,920.24, an increase from RMB 2,000,000,000.00, reflecting a growth of approximately 6.1%[106]. Environmental Compliance - The company reported a total wastewater discharge with a chemical oxygen demand (COD) concentration of less than 500 mg/L, with a total COD discharge of 111 tons per year[78]. - The company has implemented pollution discharge standards for various pollutants, ensuring compliance with environmental regulations[78]. - The company operates in compliance with the environmental protection department's regulations as a key pollutant discharge unit[77]. - The company has established three wastewater treatment facilities with a total capacity of 12,000 tons per day, and additional facilities at subsidiaries with capacities of 500 tons and 3,000 tons per day, ensuring compliance with wastewater discharge standards[81]. - The company has developed emergency response plans for environmental incidents, including fire, explosion, and hazardous material leaks[86]. Corporate Governance - The company has maintained compliance with corporate governance standards as per relevant regulations in China[67]. - The company confirmed compliance with corporate governance codes without any deviations during the reporting period[88]. - The audit committee reviewed the unaudited interim accounts for the six months ending June 30, 2024, and agreed with the financial accounting principles adopted[89]. - The company has committed to avoiding any business or activities that may lead to competition or conflicts of interest with its main business during the period of control by its major shareholder[69]. - The company ensures that all transactions with its subsidiaries and related parties are conducted on an equal, voluntary, and fair basis[70]. Risk Management - The group has implemented measures to mitigate risks related to industry policy changes, new drug development, and raw material price fluctuations[64][65][66]. - The company is enhancing compliance management and risk control systems to ensure safe development[49]. - The company has established risk response mechanisms for potential disputes related to the "Quanding Huajun" project[72]. Investment and Financing - The company has no plans for share buybacks, sales, or repurchases during the reporting period[74]. - The company raised RMB 7,724,800.00 through stock options exercised in January 2024, contributing to the increase in registered capital[111]. - The company reported a profit of RMB 8,182,200 from its financial investments during the reporting period[75]. - The company has not planned any major investments or acquisitions for the upcoming years[87]. Revenue Recognition - The company recognizes revenue when control of goods or services is transferred to the customer, indicating a focus on sales of pharmaceutical products[188]. - Domestic sales revenue is recognized upon delivery of goods to customers, ensuring that payment rights are established and collectible[189]. - For export sales, revenue is recognized when products are customs cleared and the company has obtained the necessary shipping documents, confirming control transfer[190].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 1 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited (於中華人民共和國註冊成立之股份有限公司) (股份編號：00719) | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Operating revenue for Q1 2024 was RMB 2,474,697,457.66, a decrease of 6.25% compared to RMB 2,639,665,769.78 in Q1 2023[2] - Net profit attributable to shareholders for Q1 2024 was RMB 141,879,437.62, down 6.41% from RMB 151,603,818.36 in Q1 2023[2] - Basic earnings per share for Q1 2024 were RMB 0.21, a decrease of 8.70% from RMB 0.23 in Q1 2023[3] - The total profit for Q1 2024 was RMB 168,771,522.02, compared to RMB 184,919,311.15 in Q1 2023, showing a decline in profitability[4] - Net profit attributable to the parent company was approximately $141.88 million, a decrease from $151.60 million in the previous period[5] - Total comprehensive income attributable to the parent company was approximately $142.69 million, compared to $159.49 million previously[5] - Basic earnings per share were $0.21, down from $0.23 in the prior period[5] - Total comprehensive income for the period was approximately $146.08 million, compared to $161.72 million previously[5] - Other comprehensive income after tax attributable to the parent company was approximately $807,373.60, down from $7.89 million previously[5] - The company reported a decrease in foreign currency translation adjustments, with a loss of approximately $(69,418.40)[5] Cash Flow and Assets - Net cash flow from operating activities improved significantly to RMB 38,063,364.43, compared to a negative RMB 183,742,803.27 in the same period last year, representing a 120.72% increase[2] - Total assets as of March 31, 2024, were RMB 8,467,977,386.18, reflecting a 2.19% increase from RMB 8,286,166,330.90 at the end of 2023[3] - Net assets attributable to shareholders increased by 4.65% to RMB 4,764,918,585.13 from RMB 4,553,103,869.56 at the end of 2023[3] Research and Development - Research and development expenses for Q1 2024 were RMB 141,905,763.44, compared to RMB 112,119,587.26 in Q1 2023, indicating a focus on innovation[4] Strategic Initiatives - The company plans to continue its market expansion and enhance product development strategies in the upcoming quarters[1] - The company continues to focus on strategic initiatives to enhance operational efficiency and market presence[5] Governance and Compliance - The board approved changes to accounting policies effective January 1, 2024, with no significant impact on the financial statements[6] - The company is committed to adhering to the new accounting standards as outlined by the Ministry of Finance[6] - The board of directors consists of a mix of executive and independent non-executive members, ensuring diverse governance[7] Profitability Metrics - The company reported a gross profit margin of approximately 5.89% for Q1 2024, down from 6.81% in Q1 2023[4]

Financial Performance - The financial summary for 2023 indicates that the company achieved a total revenue of RMB 1.5 billion, representing a year-on-year increase of 12%[14] - The net profit attributable to shareholders for the year was RMB 300 million, reflecting a growth of 15% compared to the previous year[14] - Operating income for 2023 reached RMB 8.1 billion, an increase of 7.97% compared to RMB 7.5 billion in 2022[17] - Total profits for 2023 amounted to RMB 532.7 million, reflecting a growth of 12.91% from RMB 471.8 million in the previous year[17] - Net profits attributable to shareholders of the listed company increased by 20.79% to RMB 496.5 million, up from RMB 411.1 million in 2022[17] - Basic earnings per share rose to RMB 0.74, representing a 19.35% increase from RMB 0.62 in 2022[17] - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year[14] - Net cash flow from operating activities decreased significantly by 65.01% to RMB 265.3 million, down from RMB 758.2 million in 2022[17] Market Expansion and Strategy - User data shows that the company expanded its customer base by 20%, reaching a total of 1.2 million active users[14] - The company has set a revenue target of RMB 1.8 billion for 2024, which would represent a growth of 20% year-on-year[14] - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2025[14] - A strategic acquisition of a local competitor is expected to enhance the company's production capacity by 25%[14] - New product development efforts have led to the launch of three innovative pharmaceutical products, contributing to 10% of total sales in 2023[14] Shareholder Information - The total number of issued shares as of December 31, 2023, was 674,682,835, an increase from 669,627,235 in 2022[30] - The top shareholder, Hualu Holdings Group Co. Ltd., held 30.36% of the shares, totaling 204,864,092 shares[43] - The second-largest shareholder, HKSCC (Nominees) Limited, held 28.65% of the shares, totaling 193,314,147 shares[43] - The top ten shareholders collectively held a significant portion of the company's shares, with no pledges or freezes reported[44] - The company had a total of 92,982 shareholders as of February 29, 2024, indicating a slight decrease in shareholder count[39] Governance and Management - The Company has a diverse board of directors with expertise in economics, law, finance, and pharmaceuticals, enhancing its strategic decision-making capabilities[74][75][80] - The Company is focused on expanding its market presence and enhancing its product offerings through strategic leadership and experienced management[72][78] - The management team is well-versed in financial operations, with the CFO, Mr. Hou Ning, having extensive experience in auditing and finance[75] - The board's composition reflects a commitment to governance and strategic oversight, essential for the Company's long-term success[78][82] - The Company has maintained a stable leadership structure with no significant changes reported during the year[103] Internal Control and Audit - The Audit Committee confirmed that the financial statements for 2023 were prepared in accordance with the accounting policies and standards, reflecting the company's assets, liabilities, and operating results accurately as of December 31, 2023[161] - Shine Wing issued a standard audit report without reservation, indicating that the financial statements accurately represent the company's financial condition and performance for 2023[170] - The company’s governance structure includes a Remuneration and Appraisal Committee, which operates under the guidelines of the Hong Kong Stock Exchange[175] - The internal control leading team is responsible for organizing and implementing internal control activities, reporting to the Board of Directors on the development and evaluation of internal control[195] - The effectiveness of internal control may change due to internal and external environmental factors, and the company has mechanisms in place to identify and rectify internal control deficiencies[200] Employee and Training Programs - As of December 31, 2023, the Group employed 7,104 staff with total wages amounting to RMB 743,778,000[128] - In 2023, the Company completed 71 corporate-level education training programs, training a total of 3,365 employees[137] - The Company has established a training system that enhances the capability and competency of staff members, ensuring efficient operation of the management system[139] - The Group's employee remuneration is determined based on national policies and the Company's financial condition, ensuring competitive compensation[128] Proposed Dividend - The proposed dividend for the year 2023 is RMB0.25 per share, subject to shareholder approval[63] - The Company is advised to exercise caution regarding the proposed dividend distribution, which may be adjusted based on changes in total issued share capital[63] - Further details regarding the proposed cash dividend will be disclosed in due course, including payment currency and applicable foreign exchange rate[64]